Sunesis Pharmaceutic (SNSS) 0.70 $SNSS
Sunesis Pharmaceuticals Reports Second Quarter 2016 Financial Results and Recent Highlights
GlobeNewswire - Fri Jul 29, 6:07AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the second quarter ended June 30, 2016. Loss from operations for the three months ended June 30, 2016 was $10.0 million. As of June 30, 2016, cash, cash equivalents and marketable securities totaled $33.1 million.
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals (SNSS) in Focus: Stock Gains 8.7%
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 7:45AM CDT
Sunesis Pharmaceuticals, Inc. (SNSS) was a big mover last session, as the company saw its shares rise over 8% on the day.
ANIP: 61.06 (+0.46), SNSS: 0.70 (+0.05)
7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.36 (unch), RTRX: 18.17 (+0.24), AVEO: 0.99 (-0.01), SNSS: 0.70 (+0.05), LGND: 138.53 (+3.65), BIND: 0.78 (-0.09), ACOR: 25.13 (-0.15)
Sunesis Announces Study Examining the Value of Complete Remission Prior to HCT in Patients with AML Presented at 2016 ASCO Annual Meeting
GlobeNewswire - Mon Jun 06, 8:12AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced the presentation of results from a study conducted by the Center for International Blood and Marrow Transplant Research (CIBMTR) at the Medical College of Wisconsin evaluating the value of achieving complete remission prior to allogeneic hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML). The study was funded jointly by Sunesis and CIBMTR. The results are being presented today, Monday, June 6 from 8:00 a.m. to 11:30 a.m. Central Time at the Hematologic Malignancies - Leukemia, Myelodyplastic Syndromes, and Allotransplant General Poster Session of the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois.
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals Appoints Linda Neuman, M.D., as Vice President, Clinical Development
GlobeNewswire - Wed Jun 01, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Linda Neuman, M.D., has been appointed to the role of Vice President, Clinical Development. Dr. Neuman brings 10 years of clinical practice and 13 years of industry experience to Sunesis, most recently serving as Senior Medical Director of Oncology at Puma Biotechnology.
SNSS: 0.70 (+0.05), PBYI: 49.04 (-0.85)
Sunesis Pharmaceuticals Announces Support of First-Ever Acute Myeloid Leukemia Awareness Month in June
GlobeNewswire - Wed May 25, 8:00AM CDT
Sunesis Provides Educational Grant to Support Campaign Sponsor CancerCare
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals Announces Oral Presentation on Vosaroxin at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 6:28AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced an oral presentation on vosaroxin at the 21 Congress of the European Hematology Association (EHA) to be held June 9-12, 2016 at the Bella Center in Copenhagen, Denmark.
SNSS: 0.70 (+0.05)
Sunesis to Present at the 2016 UBS Global Healthcare Conference
GlobeNewswire - Wed May 18, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at the 2016 UBS Global Healthcare Conference on Wednesday, May 25 at 11:00 AM Eastern Time at The Grand Hyatt in New York City.
SNSS: 0.70 (+0.05)
Sunesis reports 1Q loss
Automated Insights - Thu May 05, 8:40AM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Sunesis Pharmaceuticals Inc. (SNSS) on Thursday reported a loss of $10.1 million in its first quarter.
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals Reports First Quarter 2016 Financial Results and Recent Highlights
GlobeNewswire - Thu May 05, 6:01AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the first quarter ended March 31, 2016. Loss from operations for the three months ended March 31, 2016 was $10.1 million. As of March 31, 2016, cash, cash equivalents and marketable securities totaled $40.0 million.
SNSS: 0.70 (+0.05)
Sunesis to Host Conference Call on May 5th to Discuss First Quarter 2016 Financial Results and Recent Highlights
GlobeNewswire - Thu Apr 28, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it will host a conference call on Thursday, May 5, 2016 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2016.
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 05, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12 at 1:40 PM Eastern Time at The Westin Grand Central in New York City.
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals Announces Closing of $15 Million Venture Loan
GlobeNewswire - Fri Apr 01, 7:17AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has entered into a $15 million loan agreement ("the agreement"
with Bridge Bank, a division of Western Alliance Bank and Solar Capital Ltd. (collectively, "the lenders".
SLRC: 20.07 (-0.18), WAL: 33.85 (-0.18), SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals Appoints Geoffrey Parker to the Board of Directors
GlobeNewswire - Mon Mar 28, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Geoffrey Parker has been appointed to the Sunesis Board of Directors. Mr. Parker brings over 30 years of finance and executive leadership experience to the Board including, most recently, serving as Executive Vice President and Chief Financial Officer of Anacor Pharmaceuticals, Inc., which he joined in 2010 at the time of its initial public offering. Sunesis also announced that Helen Kim stepped down from her position as a Director.
SNSS: 0.70 (+0.05), ANAC: 99.06 (-0.14)
Sunesis Pharmaceuticals Announces First Patient Treated in Vanderbilt University-Sponsored Phase 2 VITAL Study of Vosaroxin in Combination with Infusional Cytarabine in Patients with Previously Untreated AML
GlobeNewswire - Thu Mar 24, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the first patients have been treated in the investigator-sponsored VITAL (Vosaroxin and Infusional Cytarabine for Frontline Treatment of Acute Myeloid Leukemia) Phase 2 study of vosaroxin in combination with cytarabine in patients with previously untreated acute myeloid leukemia (AML). The trial is being conducted at the Vanderbilt-Ingram Cancer Center at Vanderbilt University under the direction of Michael R. Savona, M.D., FACP, Associate Professor of Medicine and Director of Hematology Early Therapeutics Program, and Stephen A. Strickland, M.D., MSCI, Assistant Professor of Medicine.
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062
GlobeNewswire - Wed Mar 23, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the first subject has been dosed in a Phase 1A, randomized, double-blind, placebo-controlled dose-ranging study to investigate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of its oral, next-generation, non-covalently binding BTK-inhibitor, SNS-062, in healthy subjects. The Phase 1A study is being conducted in Belgium, pursuant to a Clinical Trial Application (CTA). With a successful study outcome, SNS-062 is expected to proceed to a Phase 1B/2 study in patients with B-cell malignancies later this year.
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2015 Financial Results and Recent Highlights
GlobeNewswire - Thu Mar 10, 6:00AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the fourth quarter and year ended December 31, 2015. Loss from operations for the three months and year ended December 31, 2015 was $11.3 million and $39.3 million, respectively. As of December 31, 2015, cash, cash equivalents and marketable securities totaled $46.4 million.
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals' marketing authorisation application for Vosaroxin for AML validated by EMA
M2 - Tue Jan 05, 6:03AM CST
Biopharmaceutical company Sunesis Pharmaceuticals (NasdaqCM:SNSS) said on Monday that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for vosaroxin for relapsed refractory acute myeloid leukemia (AML), a rapidly progressing cancer of the blood, in patients aged 60 years and older.
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals Reports Second Quarter 2016 Financial Results and Recent Highlights
GlobeNewswire - Fri Jul 29, 6:07AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the second quarter ended June 30, 2016. Loss from operations for the three months ended June 30, 2016 was $10.0 million. As of June 30, 2016, cash, cash equivalents and marketable securities totaled $33.1 million.
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals (SNSS) in Focus: Stock Gains 8.7%
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 7:45AM CDT
Sunesis Pharmaceuticals, Inc. (SNSS) was a big mover last session, as the company saw its shares rise over 8% on the day.
ANIP: 61.06 (+0.46), SNSS: 0.70 (+0.05)
7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.36 (unch), RTRX: 18.17 (+0.24), AVEO: 0.99 (-0.01), SNSS: 0.70 (+0.05), LGND: 138.53 (+3.65), BIND: 0.78 (-0.09), ACOR: 25.13 (-0.15)
Sunesis Announces Study Examining the Value of Complete Remission Prior to HCT in Patients with AML Presented at 2016 ASCO Annual Meeting
GlobeNewswire - Mon Jun 06, 8:12AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced the presentation of results from a study conducted by the Center for International Blood and Marrow Transplant Research (CIBMTR) at the Medical College of Wisconsin evaluating the value of achieving complete remission prior to allogeneic hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML). The study was funded jointly by Sunesis and CIBMTR. The results are being presented today, Monday, June 6 from 8:00 a.m. to 11:30 a.m. Central Time at the Hematologic Malignancies - Leukemia, Myelodyplastic Syndromes, and Allotransplant General Poster Session of the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois.
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals Appoints Linda Neuman, M.D., as Vice President, Clinical Development
GlobeNewswire - Wed Jun 01, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Linda Neuman, M.D., has been appointed to the role of Vice President, Clinical Development. Dr. Neuman brings 10 years of clinical practice and 13 years of industry experience to Sunesis, most recently serving as Senior Medical Director of Oncology at Puma Biotechnology.
SNSS: 0.70 (+0.05), PBYI: 49.04 (-0.85)
Sunesis Pharmaceuticals Announces Support of First-Ever Acute Myeloid Leukemia Awareness Month in June
GlobeNewswire - Wed May 25, 8:00AM CDT
Sunesis Provides Educational Grant to Support Campaign Sponsor CancerCare
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals Announces Oral Presentation on Vosaroxin at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 6:28AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced an oral presentation on vosaroxin at the 21 Congress of the European Hematology Association (EHA) to be held June 9-12, 2016 at the Bella Center in Copenhagen, Denmark.
SNSS: 0.70 (+0.05)
Sunesis to Present at the 2016 UBS Global Healthcare Conference
GlobeNewswire - Wed May 18, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at the 2016 UBS Global Healthcare Conference on Wednesday, May 25 at 11:00 AM Eastern Time at The Grand Hyatt in New York City.
SNSS: 0.70 (+0.05)
Sunesis reports 1Q loss
Automated Insights - Thu May 05, 8:40AM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Sunesis Pharmaceuticals Inc. (SNSS) on Thursday reported a loss of $10.1 million in its first quarter.
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals Reports First Quarter 2016 Financial Results and Recent Highlights
GlobeNewswire - Thu May 05, 6:01AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the first quarter ended March 31, 2016. Loss from operations for the three months ended March 31, 2016 was $10.1 million. As of March 31, 2016, cash, cash equivalents and marketable securities totaled $40.0 million.
SNSS: 0.70 (+0.05)
Sunesis to Host Conference Call on May 5th to Discuss First Quarter 2016 Financial Results and Recent Highlights
GlobeNewswire - Thu Apr 28, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it will host a conference call on Thursday, May 5, 2016 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2016.
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 05, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12 at 1:40 PM Eastern Time at The Westin Grand Central in New York City.
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals Announces Closing of $15 Million Venture Loan
GlobeNewswire - Fri Apr 01, 7:17AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has entered into a $15 million loan agreement ("the agreement"
with Bridge Bank, a division of Western Alliance Bank and Solar Capital Ltd. (collectively, "the lenders". SLRC: 20.07 (-0.18), WAL: 33.85 (-0.18), SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals Appoints Geoffrey Parker to the Board of Directors
GlobeNewswire - Mon Mar 28, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Geoffrey Parker has been appointed to the Sunesis Board of Directors. Mr. Parker brings over 30 years of finance and executive leadership experience to the Board including, most recently, serving as Executive Vice President and Chief Financial Officer of Anacor Pharmaceuticals, Inc., which he joined in 2010 at the time of its initial public offering. Sunesis also announced that Helen Kim stepped down from her position as a Director.
SNSS: 0.70 (+0.05), ANAC: 99.06 (-0.14)
Sunesis Pharmaceuticals Announces First Patient Treated in Vanderbilt University-Sponsored Phase 2 VITAL Study of Vosaroxin in Combination with Infusional Cytarabine in Patients with Previously Untreated AML
GlobeNewswire - Thu Mar 24, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the first patients have been treated in the investigator-sponsored VITAL (Vosaroxin and Infusional Cytarabine for Frontline Treatment of Acute Myeloid Leukemia) Phase 2 study of vosaroxin in combination with cytarabine in patients with previously untreated acute myeloid leukemia (AML). The trial is being conducted at the Vanderbilt-Ingram Cancer Center at Vanderbilt University under the direction of Michael R. Savona, M.D., FACP, Associate Professor of Medicine and Director of Hematology Early Therapeutics Program, and Stephen A. Strickland, M.D., MSCI, Assistant Professor of Medicine.
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062
GlobeNewswire - Wed Mar 23, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the first subject has been dosed in a Phase 1A, randomized, double-blind, placebo-controlled dose-ranging study to investigate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of its oral, next-generation, non-covalently binding BTK-inhibitor, SNS-062, in healthy subjects. The Phase 1A study is being conducted in Belgium, pursuant to a Clinical Trial Application (CTA). With a successful study outcome, SNS-062 is expected to proceed to a Phase 1B/2 study in patients with B-cell malignancies later this year.
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2015 Financial Results and Recent Highlights
GlobeNewswire - Thu Mar 10, 6:00AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the fourth quarter and year ended December 31, 2015. Loss from operations for the three months and year ended December 31, 2015 was $11.3 million and $39.3 million, respectively. As of December 31, 2015, cash, cash equivalents and marketable securities totaled $46.4 million.
SNSS: 0.70 (+0.05)
Sunesis Pharmaceuticals' marketing authorisation application for Vosaroxin for AML validated by EMA
M2 - Tue Jan 05, 6:03AM CST
Biopharmaceutical company Sunesis Pharmaceuticals (NasdaqCM:SNSS) said on Monday that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for vosaroxin for relapsed refractory acute myeloid leukemia (AML), a rapidly progressing cancer of the blood, in patients aged 60 years and older.
SNSS: 0.70 (+0.05)
